Glenmark Pharma to launch phase 1 trial in solid tumors for GBR 1342
Glenmark Pharmaceuticals is planning to launch a Phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342. The decision is driven by recent findings derived from a non-interventional human study utilizing a clinically validated CAN script platform. GBR 1342 is based on Glenmark’s proprietary BEAT platform and simultaneously targets CD38 and the … Read more
